Key points are not available for this paper at this time.
Named for their apparent ability to function without prior sensitization, NK cells are the newest additions to the growing cast of immunopathologic effectors, which includes antibodies and immune complexes as well as cytolytic T cells and K cells. The understanding of NK activity has progressed to a level that permits investigators to consider its clinical exploitation in antitumor therapy.
R B Herberman (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: